CRVS
NASDAQCorvus Pharmaceuticals Inc.
Price$15.45+0.35 (+2.32%)
01:30 PM07:45 PM
News · 26 weeks43+14%
2025-11-022026-04-26
Mix1990d
- SEC Filings8(42%)
- Other5(26%)
- Earnings2(11%)
- Insider2(11%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Chan Andrew C.4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chan Andrew C.3 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- SECSEC Form DEF 14A filed by Corvus Pharmaceuticals Inc.DEF 14A - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECSEC Form DEFA14A filed by Corvus Pharmaceuticals Inc.DEFA14A - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- PRCorvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of DirectorsSOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology. "The addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for ITK inhibi
- PRCorvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual MeetingTwo oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor and analyst meeting scheduled for 1:30 pm ET (12:30 pm CT) on May 14, 2026 Company to report first quarter 2026 financial results on May 7, 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that it will host an in-person and virtual investor and analyst meeting on May 14, 2026 to highlight soquelitinib data being presented at the Society for Investiga
- ANALYSTGoldman initiated coverage on Corvus Pharmaceuticals with a new price targetGoldman initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $40.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.SCHEDULE 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECSEC Form 424B5 filed by Corvus Pharmaceuticals Inc.424B5 - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECSEC Form S-3ASR filed by Corvus Pharmaceuticals Inc.S-3ASR - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECSEC Form 10-K filed by Corvus Pharmaceuticals Inc.10-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- PRCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsAnnounced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib atopic dermatitis Phase 2 trial Completed public offering raising net proceeds of $189 million, extending cash runway into the second quarter of 2028 Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended De
- PRCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d
- PRCorvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET. A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.SCHEDULE 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Corvus Pharmaceuticals Inc.SCHEDULE 13D/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
- INSIDERDirector Thompson Peter A. exercised 210,000 shares at a strike of $5.33 (SEC Form 4)4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Corvus Pharmaceuticals Inc.SCHEDULE 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Corvus Pharmaceuticals Inc.SCHEDULE 13D/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
- PRCorvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201MSOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $201.2 million, including proceeds from the full exercise of the underwriters' option to purchase additional shar
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECSEC Form 424B5 filed by Corvus Pharmaceuticals Inc.424B5 - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
CRVS FAQ
7 questionsWhat does Corvus Pharmaceuticals Inc. do?
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small...Where does CRVS stock trade?
Corvus Pharmaceuticals Inc. (CRVS) is listed on NASDAQ.What sector and industry is CRVS in?
Corvus Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Corvus Pharmaceuticals Inc. go public?
Corvus Pharmaceuticals Inc. (CRVS) completed its IPO in 2016.What are analysts saying about CRVS?
Corvus Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy with a $4000.00 price target on 2026-04-17.What companies are similar to CRVS?
Notable peers in the same industry include RCUS (Arcus Biosciences Inc.), ITOS (iTeos Therapeutics Inc.), CANF (Can-Fite Biopharma Ltd). Compare CRVS side-by-side with any of them on Quantisnow.How can I track CRVS on Quantisnow?
Quantisnow aggregates Corvus Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRVS to receive live email and push alerts on every new disclosure.